BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 23581666)

  • 1. The high price of "free" trade: U.S. trade agreements and access to medicines.
    Lopert R; Gleeson D
    J Law Med Ethics; 2013; 41(1):199-223. PubMed ID: 23581666
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How the Trans Pacific Partnership Agreement could undermine PHARMAC and threaten access to affordable medicines and health equity in New Zealand.
    Gleeson D; Lopert R; Reid P
    Health Policy; 2013 Oct; 112(3):227-33. PubMed ID: 23992756
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analyzing the impact of trade and investment agreements on pharmaceutical policy: provisions, pathways and potential impacts.
    Gleeson D; Lexchin J; Labonté R; Townsend B; Gagnon MA; Kohler J; Forman L; Shadlen KC
    Global Health; 2019 Nov; 15(Suppl 1):78. PubMed ID: 31775767
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Public health-oriented intellectual property and trade policies in Africa and the regional mechanism under Trade-Related Aspects of Intellectual Property Rights amendment.
    Adekola TA
    Public Health; 2019 Aug; 173():1-4. PubMed ID: 31203136
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Regional Comprehensive Economic Partnership, Intellectual Property Protection, and Access to Medicines.
    Townsend B; Gleeson D; Lopert R
    Asia Pac J Public Health; 2016 Nov; 28(8):682-693. PubMed ID: 27920239
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patents, pills and politics: the Australia-United States Free Trade Agreement and the Pharmaceutical Benefits Scheme.
    Harvey K
    Aust Health Rev; 2004 Nov; 28(2):218-26. PubMed ID: 15527402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protecting Pharmaceutical Patents and Test Data: How the Trans-Pacific Partnership Agreement Could Affect Access to Medicines in the US and Abroad.
    Luo J; Kesselheim AS
    AMA J Ethics; 2016 Jul; 18(7):727-35. PubMed ID: 27437823
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Moderating the impact of patent linkage on access to medicines: lessons from variations in South Korea, Australia, Canada, and the United States.
    Son KB; Lopert R; Gleeson D; Lee TJ
    Global Health; 2018 Oct; 14(1):101. PubMed ID: 30355313
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Essential medicines and the TRIPS Agreement: collision between the right to health and intellectual property rights].
    Allard Soto R
    Salud Colect; 2015 Mar; 11(1):9-21. PubMed ID: 25853827
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact on access to medicines from TRIPS-Plus: a case study of Thai-US FTA.
    Kessomboon N; Limpananont J; Kulsomboon V; Maleewong U; Eksaengsri A; Paothong P
    Southeast Asian J Trop Med Public Health; 2010 May; 41(3):667-77. PubMed ID: 20578557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trans-Pacific Partnership Provisions in Intellectual Property, Transparency, and Investment Chapters Threaten Access to Medicines in the US and Elsewhere.
    Baker BK
    PLoS Med; 2016 Mar; 13(3):e1001970. PubMed ID: 26954325
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Evolution of the international intellectual property rights system: patent protection for the pharmaceutical industry and access to medicines].
    Chaves GC; Oliveira MA; Hasenclever L; de Melo LM
    Cad Saude Publica; 2007 Feb; 23(2):257-67. PubMed ID: 17221075
    [TBL] [Abstract][Full Text] [Related]  

  • 13. What is the impact of intellectual property rules on access to medicines? A systematic review.
    Tenni B; Moir HVJ; Townsend B; Kilic B; Farrell AM; Keegel T; Gleeson D
    Global Health; 2022 Apr; 18(1):40. PubMed ID: 35428250
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of the World Trade Organization TRIPS agreement on the pharmaceutical industry in Thailand.
    Supakankunti S; Janjaroen WS; Tangphao O; Ratanawijitrasin S; Kraipornsak P; Pradithavanij P
    Bull World Health Organ; 2001; 79(5):461-70. PubMed ID: 11417042
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Looking inward: regional parallel trade as a means of bringing affordable drugs to Africa.
    Buckely M
    Seton Hall Law Rev; 2011; 41(2):625-69. PubMed ID: 21739760
    [No Abstract]   [Full Text] [Related]  

  • 16. Addressing legal and political barriers to global pharmaceutical access: options for remedying the impact of the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) and the imposition of TRIPS-plus standards.
    Cohen-Kohler JC; Forman L; Lipkus N
    Health Econ Policy Law; 2008 Jul; 3(Pt 3):229-56. PubMed ID: 18634618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Defending access to medicines in regional trade agreements: lessons from the Regional Comprehensive Economic Partnership - a qualitative study of policy actors' views.
    Townsend B
    Global Health; 2021 Jul; 17(1):78. PubMed ID: 34238347
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Balancing public health, trade and intellectual monopoly privileges: recent Australian IP legislation and the TPPA.
    Vines T; Crow K; Faunce T
    J Law Med; 2012 Dec; 20(2):280-94. PubMed ID: 23431847
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Has the implementation of the TRIPS Agreement in Latin America and the Caribbean produced intellectual property legislation that favours public health?
    Oliveira MA; Bermudez JA; Chaves GC; Velásquez G
    Bull World Health Organ; 2004 Nov; 82(11):815-21. PubMed ID: 15640916
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The trends and constructive ambiguity in international agreements on intellectual property and pharmaceutical affairs: Implications for domestic legislations in low- and middle-income countries.
    Son KB; Lee TJ
    Glob Public Health; 2018 Sep; 13(9):1169-1178. PubMed ID: 28585477
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.